Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Matthew Maurer, MD
Myeloid Therapeutics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- St Vincent'S Public Hospital Sydney
Darlinghurst, New South Wales, Australia
Recruiting - Scientia Clinical Research Ltd
Randwick, New South Wales, Australia
Charlotte Lemech, MDRecruiting - Westmead Hospital
Westmead, New South Wales, Australia
Adnan Nagrial, MDRecruiting - Souther Oncology Clinical Research Unit (socru)
Bedford Park, South Australia, Australia
Recruiting - Cabrini Health
Malvern, Victoria, Australia
Gary Richardson, MDRecruiting - Linear Clinical Research Ltd
Nedlands, Western Australia, Australia
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 2 Aug 2023
- Primary completion
- 31 Aug 2027
- Completion
- 31 Aug 2028
- Last update posted
- 18 Jan 2024
- Registered enrollment
- 48
- Registry id
- NCT05969041
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.